CAR-TCR Summit Europe 2021 | Analysing trends in the CAR-TCR landscape
Vasiliki Zochiou, PharmD, Beacon Targeted Therapies, London, UK, provides an overview of her presentation at the CAR-TCR Summit Europe 2021 focused on the evolution of the CAR-T and T-cell receptor (TCR) research landscape in recent years and how it has been impacted by the COVID-19 pandemic. Data suggests that in the last year, there has been a significant shift in the field toward allogeneic approaches and there has been rise in the number of allogeneic cell therapies that have entered preclinical pipelines and the clinic. Another growing trend in the field is the development of next-generation CAR therapies and research into construct design, manufacturing and armored CAR T-cells. This interview took place during the CAR-TCR Summit Europe 2021.
Disclosures
Vasiliki Zochiou is an employee of Beacon Targeted Therapies, London, UK, a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals, tracking targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development. The data on Beacon is curated and updated from publicly available sources within 24 – 48 hours of publication.
